{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Assessment of rheumatoid arthritis management using biologicals by rheumatologists across India (RESTART Study)

Survey Questionnaire Form
Doctor’s details

Questionnaire

  1. With which of the following statements regarding rheumatoid arthritis (RA) phenotype in India you agree the most? (Multiple options can be selected)

  2. How many new patients of rheumatoid arthritis do you see in a month in your clinical practice? *

  3. What proportion of rheumatoid arthritis patients in your practice belong to moderate to severely active rheumatoid arthritis category in a month? *

  4. Which tests and examinations do you do to diagnose rheumatoid arthritis? (Multiple options can be selected) *

  5. How severity of RA is ascertained as moderate to severe in your practice? (Multiple options can be selected) *

  6. What proportion of rheumatoid arthritis patients in your practice present with extra articular manifestations? *

  7. Which extra articular manifestations are common in rheumatoid arthritis in your practice? (Multiple options can be selected) *

  8. Which guidelines do you follow in your clinical practice for the management of rheumatoid arthritis? *

  9. What proportion of rheumatoid arthritis patients do not adequately respond to methotrexate in your practice? *

  10. What proportion of rheumatoid arthritis patients are methotrexate intolerant in your practice? *

  11. When do you prescribe adalimumab in the management of moderately to severely active rheumatoid arthritis? *

  12. What are the parameters do you think which are favourable for adalimumab in the management of moderately to severely active rheumatoid arthritis? (Multiple options can be selected) *

  13. What is your preferred regimen for the management of moderately to severely active rheumatoid arthritis with adalimumab? *

  14. What do you prefer when patients of rheumatoid arthritis with poor prognostic factors like high swollen joint count, high acute phase reactant levels etc. do not adequately respond to conventional synthetic DMARDs? *

  15. What is the average duration of adalimumab therapy for the management of rheumatoid arthritis in your practice? (Multiple options can be selected) *

  16. What is the maximum duration of adalimumab use in your practice for the management of rheumatoid arthritis? *

  17. How long does it take to get clinical remission with adalimumab in moderately to severely active rheumatoid arthritis? *

  18. What percentage of moderately to severely active rheumatoid arthritis patients do not adequately respond to adalimumab in your practice? *

  19. What are the causes of inadequate response to adalimumab in patient with rheumatoid arthritis as per your experience? (Multiple options can be selected) *

  20. High concentration adalimumab i.e. 40 mg in 0.4 ml improves patient compliance as compared to low concentration adalimumab i.e. 40 mg in 0.8 ml as there is less injection related pain due to less volume is injected with high concentration *

  21. High concentration adalimumab has favourable safety profile (lower incidence of injection site reactions or other adverse effects) compared to low concentration adalimumab *

  22. What is your observation about the efficacy of high concentration adalimumab compared to low concentration adalimumab in the management of rheumatoid arthritis? *

  23. What is your expectation from biological DMARDs in rheumatoid arthritis management? (Multiple options can be selected) *

  24. What is your experience about the development of anti-drug antibodies (ADA) with adalimumab and decrease in its efficacy? *

  25. What is your approach towards patient who relapsed after stopping treatment with adalimumab for rheumatoid arthritis? *

  26. What is your approach to prevent reactivation of pulmonary or extra pulmonary tuberculosis with adalimumab? *

  27. What diagnostic tests do you use to screen latent tuberculosis infection before initiating treatment with TNF-α blockers? (Multiple options can be selected) *

  28. What do you do to reduce the risk of bacterial, viral and fungal infections with adalimumab in the management of rheumatoid arthritis? (Multiple options can be selected) *

  29. What do you do if infection develops during treatment with adalimumab? *

  30. What approach is followed to minimize/ avoid risk of malignancies during treatment with adalimumab? *

  31. Which of the following anti-rheumatoid agent is preferred when cardiac condition is present as extra articular manifestations in your patient with rheumatoid arthritis? *

  32. How do you manage pulmonary diseases as extra articular manifestations of rheumatoid arthritis? *

  33. How do you manage cutaneous diseases as extra articular manifestations of rheumatoid arthritis? *

  34. How do you manage ocular diseases as extra articular manifestations of rheumatoid arthritis? *